REGN Operating cash flow
Operating cash flow at Regeneron Pharmaceuticals rose to $5.0B in fiscal 2025, from $4.4B in 2024.
Net cash provided by operating activities, as filed.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities · EDGAR CompanyFacts · CIK 872589 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$5.0B
FY2024 $4.4B
HIGH$7.1B FY2021
LOW$4.4B FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Change |
|---|---|---|
| FY2025 | $5.0B | +$558M |
| FY2024 | $4.4B | $-174M |
| FY2023 | $4.6B | $-421M |
| FY2022 | $5.0B | $-2.1B |
| FY2021 | $7.1B | — |
More SAME DATA, OTHER VIEWS
Operating cash flow across coverage → · REGN company view →
Revenue · Net income · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.